Clinical trials: sponsored by Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo.
- Trial name
- NCT02091362
- Testing
- LY2409021, Metformin
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 270 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study of LY3016859 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of LY3016859 administered as single doses, and to determine how long LY3016859 remains in the body
- Trial name
- NCT01545583
- Testing
- LY3016859 intravenous, LY3016859 subcutaneous
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein).
- Trial name
- NCT01742091
- Testing
- LY2541546 - SC, LY2541546 - IV
- Where
- 5 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus, Connective Tissue Disease
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in participants with active SLE.
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Trial name
- NCT01205438
- Testing
- LY2127399
- Where
- 185 sites in United States, Australia and 19 more
- Volunteers
- 1,124 people
- Sponsor
- Eli Lilly and Company
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
This multicenter study will enroll approximately 185 participants with metastatic or advanced sarcoma, to assess the effectiveness and safety of IMC-A12 monotherapy for this indication.
- Conditions
- Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma
- Trial name
- NCT00668148
- Testing
- IMC-A12 (cixutumumab)
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 113 people
- Sponsor
- Eli Lilly and Company
Melanoma
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
- Trial name
- SUMMIT-1 (NCT01006252)
- Testing
- Tasisulam-sodium, Paclitaxel
- Where
- 122 sites in United States, Australia and 16 more
- Volunteers
- 336 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
- Trial name
- NCT00992225
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study of LY3025876 in Healthy Volunteers
This trial is conducted in Singapore. The aim of this trial is to evaluate the safety and tolerability of the study drug in healthy people and investigate how much of the study drug gets into the blood stream and how long it…
- Trial name
- NCT01528124
- Testing
- LY3025876
- Where
- Singapore
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
The purpose(s) of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given in multiple doses, subcutaneously (SC) (by inserting a needle just under…
- Trial name
- NCT02109042
- Testing
- Blosozumab
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
- Trial name
- NCT00785928
- Testing
- LY2127399
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Linagliptin as Add on to Basal Insulin in the Elderly
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older…
- Trial name
- NCT02240680
- Testing
- linagliptin
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Non-drug Methods Study in Participants With Alzheimer's Disease
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs…
- Trial name
- NCT01459016
- Testing
- PET scan using florbetapir, MRI Scan
- Where
- 16 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Lupus Erythematosus, Systemic
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks.
- Trial name
- NCT02041091
- Testing
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Where
- 44 sites in United States, Puerto Rico and 1 more
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus, Connective Tissue Disease
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in participants with active SLE.
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Trial name
- NCT01196091
- Testing
- LY2127399, Standard of Care
- Where
- 192 sites in United States, Argentina and 21 more
- Volunteers
- 1,164 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
An Open Label Study for Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis.
- Trial name
- NCT01215942
- Testing
- LY2127399
- Where
- 327 sites in United States, Argentina and 25 more
- Volunteers
- 1,086 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Participants with metastatic Colorectal Cancer (mCRC) who have progressed on a prior Anti-epidermal growth factor receptor (EGFR) regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess…
- Trial name
- NCT00503685
- Testing
- IMC-A12, cetuximab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Muscular Atrophy
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip…
- Trial name
- NCT01369511
- Testing
- LY2495655
- Where
- 45 sites in United States, Austria and 9 more
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.